TECH.NASDAQBio-techne CORP

Form 4: BIO-TECHNE CEO Exercises Options, Increases Direct Shareholding

Sentiment:

Insider Transaction Report

📋All filings for Bio-techne CORP
🔒Login to Follow

BIO-TECHNE Corp's CEO, Kim Kelderman, exercised stock options and increased direct beneficial ownership of common stock, while also disposing of shares to cover tax liabilities.

Summary

  • Kim Kelderman, Chief Executive Officer and Director of BIO-TECHNE Corp (TECH), completed an insider transaction on July 15, 2025.
  • Kelderman exercised 36,132 stock options at an exercise price of $44.33 per share.
  • Concurrently, 32,933 shares of common stock were disposed of at a price of $51.42 per share, which is a common practice for covering tax obligations or exercise costs.
  • Following these transactions, Kelderman's direct beneficial ownership of BIO-TECHNE common stock increased by a net of 3,199 shares, resulting in a total direct holding of 42,203 shares.
  • Kelderman continues to hold a significant number of derivative securities, including various stock options and restricted stock units, with diverse vesting schedules extending through 2028 and expiration dates up to 2034.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a significant number of shares were disposed of, this was likely for tax purposes, and the CEO still increased their direct beneficial ownership, indicating continued commitment to the company.

Positives

  • The CEO increased their direct beneficial ownership of common stock by 3,199 shares, indicating continued alignment with shareholder interests.
  • The exercise of options suggests confidence in the company's future performance, as the CEO chose to convert options into shares.

Negatives

  • A significant portion of the acquired shares (32,933 out of 36,132) were immediately disposed of, which, while common for tax purposes, reduces the net increase in direct ownership.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

  • Shareholders: The increase in direct beneficial ownership by the CEO aligns management's interests with shareholders. The disposition for tax purposes is a standard practice and not indicative of a lack of confidence.

Next Steps

  • Continued vesting of various stock options and restricted stock units on specified future dates, contingent on performance goals for some.

Key Dates

DateDescription
08/06/2022Vesting date for 6,484 stock options.
08/06/2023Vesting date for 6,484 stock options.
08/15/2023Vesting date for 7,236 stock options.
08/15/2024Vesting date for 7,236 stock options.
08/15/2024Vesting date for 7,348 stock options.
11/01/2024Vesting date for 9,563 stock options.
02/01/2025Vesting date for 12,973 stock options.
07/15/2025Date of stock option exercise and common stock disposition.
07/17/2025Date of SEC Form 4 filing signature.
08/06/2025Vesting date for 6,488 stock options.
08/15/2025Vesting date for 7,232 stock options.
08/15/2025Vesting date for 17,265 stock options.
08/15/2025Vesting date for 8,543 restricted stock units.
08/15/2025Vesting date for Performance Restricted Stock Units and Performance Stock Options if certain performance goals are achieved.
08/08/2025Expiration date for exercised stock options.
11/01/2025Vesting date for 9,563 stock options.
02/01/2026Vesting date for 12,972 stock options.
08/15/2026Vesting date for 7,236 stock options.
08/15/2026Vesting date for 7,347 stock options.
08/15/2026Vesting date for 17,265 stock options.
08/15/2026Vesting date for 8,543 restricted stock units.
08/15/2026Vesting date for Performance Restricted Stock Units and Performance Stock Options if certain performance goals are achieved.
08/07/2026Expiration date for stock options.
11/01/2026Vesting date for 9,563 stock options.
02/01/2027Vesting date for 12,973 stock options.
08/05/2027Expiration date for stock options.
08/15/2027Vesting date for 7,348 stock options.
08/15/2027Vesting date for 17,265 stock options.
08/15/2027Vesting date for 8,544 restricted stock units.
08/15/2027Vesting date for Performance Restricted Stock Units if certain performance goals are achieved.
11/01/2027Vesting date for 9,563 stock options.
02/01/2028Vesting date for 12,972 stock options.
08/06/2028Expiration date for stock options.
08/15/2028Vesting date for 17,266 stock options.
08/15/2029Expiration date for Performance Stock Options and Stock Options.
08/15/2030Expiration date for Performance Stock Options and Stock Options.
11/01/2030Expiration date for stock options.
02/01/2031Expiration date for Performance Stock Options and Stock Options.
08/15/2034Expiration date for stock options.

Recommendation

hold

Keywords

BIO-TECHNE, TECH, Kim Kelderman, SEC Form 4, insider trading, stock options, restricted stock units, beneficial ownership, CEO, director, equity compensation, shareholding

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.